News

The support and expertise of Clinical Nurse Specialists (CNSs) is at the heart of ovarian cancer care. Celebrate them with us through our new award.

Gynae Cancer Awareness Month is from 1-30 September and is a chance to shine a spotlight on ovarian cancer as one of the five gynaecological cancers.

Hear first-hand from husband and wife, Declan and Pauline, about how our supportive services helped them individually and together.

Learn about our newly launched tools and resources that put support and trusted information in the spotlight. Introducing our new stages tool, PARP inhibitor eligibility tool and Your Wellbeing hub. 

From diagnosis and wait times, to accessing the best treatments available, we recognise that there is still a significant variation in experience across the UK. We want to change this.

Led by Professor James Brenton, this project explored the immune system and its potential to transform ovarian cancer treatments by learning more about high-grade serous ovarian cancer (HGSOC) tumours. 

Target Ovarian Cancer’s Research Manager, Emma Dennett, writes about the importance of publications and how they can be used as an early indication of the impact of our ovarian cancer research.

Led by Professor Charlie Gourley and Dr Robb Hollis, this project set out to understand more about the biology of low grade serous ovarian cancer in order to find new treatment options. 

Olaparib (Lynparza®) will be available long term on the NHS in England, Northern Ireland and Wales, from the second line of ovarian cancer treatment.

Target Ovarian Cancer's Senior Healthcare Engagement Officer, Amy Schofield, writes about the recent Public Care and Public Health conference in May 2023.

Caitlin's sharing her mum's story to raise awareness of ovarian cancer symptoms in the hope that others may recognise them in themselves or others.

A new research project awarded funding from Target Ovarian Cancer is exploring immunotherapy for high grade serous ovarian cancer.